Skip to main content

Teva shares surge 5% on news of patent settlement with Neos over ADHD drug

Shares of generic drug maker Teva Pharmaceuticals Industries Ltd. rose about 5% Wednesday on news of a settlement and licensing agreement with Neos Therapeutics Inc. to resolve a patent dispute about a treatment for attention deficit disorders, or ADHD.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.